Thursday, Jul 02, 2020 | Last Update : 12:15 PM IST

100th Day Of Lockdown

Maharashtra180298931548053 Tamil Nadu94049529261264 Delhi89802599922803 Gujarat33318240381869 Uttar Pradesh2405616629718 West Bengal1917012528683 Rajasthan1831214574421 Telangana173578082267 Karnataka165148065253 Andhra Pradesh152526988193 Haryana1494110499240 Madhya Pradesh1386110655581 Bihar10204781173 Assam8956583212 Jammu and Kashmir76954856105 Odisha7316535333 Punjab56683989149 Kerala4594243626 Uttarakhand2791190937 Chhatisgarh2339193713 Jharkhand2339160512 Tripura140110931 Manipur12605790 Goa11984783 Himachal Pradesh9796179 Puducherry73930112 Nagaland5351820 Chandigarh4463676 Arunachal Pradesh182601 Mizoram1601230 Sikkim88490 Meghalaya50421
  World   Americas  06 May 2020  Trump administration ignored COVID-19 warnings, alleges fired American scientist

Trump administration ignored COVID-19 warnings, alleges fired American scientist

Published : May 6, 2020, 9:35 am IST
Updated : May 6, 2020, 9:35 am IST

Scientist in US turns whistleblower against government's decision to flood its market with malaria drug without proper inspection

US President Donald Trump. (AFP)
 US President Donald Trump. (AFP)

Washington: Top health officials of the Trump administration repeatedly ignored multiple warnings with regard to the coronavirus pandemic, including the alleged poor quality of malaria drug hydroxychloroquine from India and Pakistan, a fired American scientist has said in a whistleblower complaint.

In a complaint filed on Tuesday before the US Office of Special Counsel, which oversees protection of whistleblowers, Rick Bright alleged that top officials of the Department of Health and Human Services repeatedly ignored his messages and that of others with regard to personal protective equipment and medicines like hydroxychloroquine in particular.


When fired, Bright was head of the Biomedical Advanced Research and Development Authority, a research agency within the Health and Human Services (HHS) Department. He reported directly to Robert Kadlec, the assistant secretary of preparedness and response at the US Department of Health and Human Services.

"Dr Bright remained extremely concerned about the drug's importation from Pakistan and India because the FDA had not inspected the drugs or the factory that produced them," the complaint said.

"In Dr Bright's experience, drugs from uninspected factories can be contaminated or dosed improperly, and this could obviously be dangerous to those who took the medication. Apparently unconcerned about this known danger, Dr Kadlec and others in the administration sought to 'flood' the marketplace with these drugs," it alleged.

The Trump administration has imported nearly five crore units of the malaria drug, hydroxychloroquine, which in March had received Emergency Use Authorisation from the US Food and Drug Administration (FDA).

The Trump administration, the complaint said, was not interested in hearing from Bright and his department or subject matter experts.

"Dr Bright and his team had apparently spent all their political capital in their effort to limit chloroquine and rushing into a potentially dangerous situation and that there was no one to help stop the push to 'flood' the country with this unproven and potentially dangerous drug," the complaint said.

"He concluded that his only remaining avenue was to share his concerns with the journalist who understood the specific issue and risks associated with these drugs and who had already gathered substantial information from multiple sources," it added.

The complaint alleged that HHS Secretary Alex Azar's directive to secure a Nationwide Expanded Access IND protocol for chloroquine, based on scant scientific evidence and on such a short time-frame, sent Bright and his colleagues scrambling.

Within the hour, Bright had called a meeting of Dr Linda Lambert, Chief Medical Officer Dr Robert Walker, Director of Regulatory and Quality Affairs Dr Tremel Faison, and Drs Johnson, Disbrow and Houchens to discuss the directive.

The group expressed serious concerns about a Nationwide Expanded Access IND protocol for chloroquine given the lack of clinical data available about its therapeutic benefits and concerns about its potential safety risks, especially if administered without close physician supervision, it said.

Bright and his FDA colleagues were also concerned about the quality and potential toxicity of the chloroquine supplies produced and shipped in from facilities in India and Pakistan that were not approved by the FDA and therefore, not approved to be used in the US marketplace.

The HHS clinical and regulatory expert teams worked frantically for 48 hours without sleep to come up with a plan that would ensure the greatest level of safety for people who received this drug.

They discussed narrower options for the rollout, including a small pilot study, and established an inter-agency working group of clinical and regulatory experts to determine the safest way to make the unproven drug available without causing harm to the American public, the complaint said.

When fired earlier, Bright alleged that he was ousted because of his "insistence" that the government spend funds on "safe and scientifically-vetted solutions" to address the coronavirus crisis and not on "drugs, vaccines and other technologies that lack scientific merit".

Tags: rick bright, scientist, coronavirus, covid-19, hydroxychloroquine, malaria drug, warnings, india, pakistan
Location: United States, Washington, Seattle